Kalbe Farma Tbk PTKLBF:JKT

1,730
20.00 / 1.14%
71.39m
23.57%
0.9304
Close in IDRToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jul 25 2014 10:11 BST.

Consensus recommendation

As of Jul 25, 2014, the consensus forecast amongst 25 polled investment analysts covering Kalbe Farma Tbk PT advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Dec 07, 2012. The previous consensus forecast advised investors to hold their position in Kalbe Farma Tbk PT.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy8
Outperform6
Hold8
Underperform2
Sell0
No opinion0

Share price forecast

The 15 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,650, with a high estimate of 2,000 and a low estimate of 1,090. The median estimate represents a -4.62% decrease from the last price of 1,730. View Full Financials

High+15.6 %2,000
Med-4.6 %1,650
Low-37.0 %1,090

Dividends

In 2013, Kalbe Farma Tbk PT reported a dividend of 17.00 IDR, which represents a 10.53% decrease from last year. The 15 analysts covering the company expect dividends of 19.70 IDR for the upcoming fiscal year, an increase of 15.89%. View Full Financials

Div growth (TTM)-10.53%
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Apr 30, 2014, Kalbe Farma Tbk PT reported 1st quarter 2014 earnings of 11.00 per share.
The next earnings announcement is expected on Jul 29, 2014. View Full Interim Financials

Average growth rate+2.79%

Kalbe Farma Tbk PT reported annual 2013 earnings of 41.00 per share on Mar 27, 2014. View Full Annual Financials

Average growth rate+21.12%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

PT Kalbe Farma Tbk had 1st quarter 2014 revenues of 4.07bn. This bettered the 4.06bn consensus of the 2 analysts covering the company. This was 10.87% below the prior year's 1st quarter results. View Full Interim Financials

Average growth rate+4.38%

PT Kalbe Farma Tbk had revenues for the full year 2013 of 16.00bn. This was 17.35% above the prior year's results. View Full Annual Financials

Average growth rate+15.48%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.